Navigation Links
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Date:12/18/2009

to have entered into a great partnership with Ambit," stated Masafumi Nogimori, president and chief executive officer of Astellas. "We believe that AC220, as the most selective and advanced FLT3 kinase inhibitor, has the potential to provide a new treatment option for AML where high unmet medical needs exist. Astellas is strongly committed to focus on oncology and this partnership is a significant milestone to establish our franchise in oncology."

"With their strategic commitment to the development and commercialization of innovative oncology products, Astellas is an ideal partner for Ambit," said Scott Salka, Chief Executive Officer of Ambit Biosciences. "This collaboration establishes a comprehensive and global leadership position in the discovery and development of FLT3 kinase inhibitors, and we look forward to working closely with Astellas to explore the clinical utility of AC220 in AML and other indications."

About AC220

AC220, Ambit's lead product candidate, is being developed in collaboration with Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable second-generation FLT3 inhibitor. AC220 is currently under evaluation in a Phase 2 clinical trial designed to support potential registration of AC220 as monotherapy treatment in adult and elderly patients with relapsed/refractory AML that have the internal tandem duplication (ITD) mutation in the FLT3 kinase. AML is one of the most common types of blood cancers in adults, and the FLT3 kinase is mutated and constitutively activated in 25-40 percent of such patients. FLT3 ITD mutations predict poor prognosis and decreased response to existing treatments, including chemotherapy and hematopoietic stem cell transplant. Ambit leveraged KINOMEscan(TM), the company's proprietary, high-throughput method for screening small molecule compounds against a large number of human kinases, to advance AC220 from initial chemistry to clinical candi
'/>"/>

SOURCE Ambit Biosciences Corporation; Astellas Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
3. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
4. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
5. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
6. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
9. Cell Biosciences Completes Acquisition of Alpha Innotech
10. Neurocrine Biosciences Reports Third Quarter 2009 Results
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... it has entered into a distribution agreement with ... its dehydrated human amnion/chorion membrane ("dHACM") allograft products ... a private label basis. The MiMedx ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... 28 Cara Therapeutics, Inc. today,announced that ... trial of its long-acting,peripheral kappa opioid receptor ... will evaluate the safety, tolerability, pharmacokinetic,profile, and ... placebo-controlled, single escalating intravenous dose study in,58 ...
... Significant Improvements With ROX-828 In Migraine Pain ... Symptoms For Up to 48 Hours Vs. Placebo, ... today,announced positive top-line data from a clinical study of ... of migraine,and related symptoms., The placebo-controlled proof of ...
Cached Medicine Technology:Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 3
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the ... of its Fiber Transport Services, adding Point of Presence ... establishing a PoP at Cermak, IFN enables interconnect opportunities ... high bandwidth fiber transport service to US and Global ... President of Sales and Marketing August Zehner, establishing a ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered with ... Coach Christi Hall to campus. , Hall’s journey to a ... gaining weight as a result of years of medication. Through ... nutrition. One year later she had lost 50 pounds, lowered ... and cardio. , After joining the YMCA staff, she furthered ...
(Date:9/19/2014)... Newport News, Va. (PRWEB) September 19, 2014 ... at Warwick Forest, a skilled nursing center that offers rehabilitation ... But they will this weekend when a young couple marries ... together and with their combined 140 years of marriage have ... , Sarah Horky, 18, and Dan Eads, 20, may ...
(Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
(Date:9/18/2014)... OR (PRWEB) September 18, 2014 Active ... 50 and older as fully participating members of society ... lifestyle. To celebrate, The Stafford – a boutique retirement ... 97034 – will host two screenings of Cyber-Seniors - ... excited for our residents to watch this great film,” ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
... leaders in diagnosing and treating Lyme disease, has launched a new website ... treatment and cure of this highly debated disease. , ... Havertown, PA ... launched a new web site today that is dedicated to giving advanced, ...
... been named president of RetireSafe, a national bipartisan, non-profit ... the options and benefits of retired and retiring Americans ... He has served as a member of the ... providing leadership in multiple areas that engage all facets ...
... patient-centered CERWASHINGTON, May 19 Joining ... the New Democrat Coalition, Tony Coelho, chairman of ... with reporters and announced PIPC,s support for the ... an important step forward for patients and caregivers, ...
... small study , , TUESDAY, May 19 (HealthDay News) -- ... restored blood flow to hearts with blocked arteries for ... reported. , "I think this is very good news ... line and have no options left," said Dr. Douwe ...
... /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of ... its primary supplier, Atomic Energy of Canada Limited ... medical isotopes, primarily molybdenum-99 (Mo-99) used in the ... MDS Nordion that they anticipate the National Research ...
... First, New York State nonprofit outpatient clinics ... Medicaid, Medicaid managed care, Medicare, and insurance billing ... healthiest organization. Millin Associates ( www.millinmedical.com ... for 27 years, provides expanded services and next-generation ...
Cached Medicine News:Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:RetireSafe Names Thair Phillips as President 2Health News:PIPC Supports New Comparative Effectiveness Research (CER) Bill 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 3Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 2Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 3Health News:Nonprofit Outpatient Clinics and Social Service Agencies Outsource Billing to Increase Profits 2
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: